Active Ingredient: DEUCRAVACITINIB
In a randomized, partially double-blind, 4-period crossover Thorough QT study in healthy adults, single therapeutic (12 mg) and supratherapeutic (36 mg) oral doses were evaluated against moxifloxacin (400 mg). Deucravacitinib did not produce QTcF prolongation exceeding the 10-ms clinical threshold at either dose level. No clinically relevant effects on other ECG parameters were reported, confirming its safe ventricular repolarization profile.
https://doi.org/10.1002/cpdd.1056